GILEAD SCIENCES EN LAKEFRONT RONDEN DE OVERNAME VAN OURO MEDICINES AF OM DE PIJPLIJN OP HET GEBIED VAN ONTSTEKINGEN VERDER UIT TE BREIDEN
View original at globenewswire.comGILEAD SCIENCES EN LAKEFRONT RONDEN DE OVERNAME VAN OURO MEDICINES AF OM DE PIJPLIJN OP HET GEBIED VAN ONTSTEKINGEN VERDER UIT TE BREIDEN Bedrijven gaan samenwerken aan de ontwikkeling van gamgertamig, een potentieel first-in-class en best-in-class T-cel-engager voor auto-immuunziekten Foster City, Californië en Mechel…
What we drew from this source
The claims Via News extracted from this document. We point to the source; we don't replace it.
The addition of gamgertamig builds on Gilead's long-term strategy of investing in differentiated science and accelerating the development of therapies that address a significant unmet need
60% confidenceGamgertamig is expected to enter registration studies in 2027
60% confidenceThe transaction allows Lakefront to deploy at least $500 million of available cash independently of Gilead and outside the OLCA and Ouro transaction framework, including up to $150 million for share buybacks
60% confidenceThe Ouro acquisition, combined with existing expertise in immunology and cell therapy, supports Gilead's ambition to shift treatment paradigms from the management of chronic diseases toward the potential for a durable immune reset
60% confidenceThe Ouro portfolio will form the basis of Lakefront's R&D pipeline
60% confidenceAfter the transaction, Lakefront will still have the majority of its cash available for additional strategic transactions and other capital allocation priorities
60% confidenceGilead is active in more than 35 countries worldwide
60% confidenceLakefront's cash balance is expected to be approximately €2 billion at end of 2026
60% confidenceIn 2025, Gilead announced a planned investment of $32 billion to further strengthen its US presence and drive the next phase of discoveries, employment and public health preparedness
60% confidenceGamgertamig has the potential to be a first-in-class and best-in-class T-cell engager for auto-immune diseases
60% confidenceGamgertamig is designed to enable rapid and deep depletion of plasma cells and B-cells following a limited subcutaneously administered treatment course, with the potential to induce durable disease control in severe antibody-mediated rare diseases
60% confidence